Oaktree Acquisition Corp III Life Sciences
OACC
51 hedge funds and large institutions have $179M invested in Oaktree Acquisition Corp III Life Sciences in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
4% more funds holding
Funds holding: 49 → 51 (+2)
0.25% more ownership
Funds ownership: 85.19% → 85.44% (+0.25%)
0% more capital invested
Capital invested by funds: $179M → $179M (+$253K)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FBCM
Fort Baker Capital Management
Larkspur,
California
|
+$10.6M |
| 2 |
DAM
Decagon Asset Management
London,
United Kingdom
|
+$3.48M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$868K |
| 4 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
+$225K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$109K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$7.12M |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$1.9M |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$1.24M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.06M |
| 5 |
Millennium Management
New York
|
-$1.05M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Morgan Stanley
New York
| $794 | +$224 | +21 | +39% |
|
|
DCM
52
Driehaus Capital Management
Chicago,
Illinois
| – | -$7.12M | -670,072 | Closed |
|
|
CC
53
Centiva Capital
New York
| – | -$429K | -40,400 | Closed |
|
OACC Hedge Fund Activity: Q1 2026 in Review
51 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Oaktree Acquisition Corp III Life Sciences (OACC) for Q1 2026, worth a combined $179M — up 0.14% from $179M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new OACC positions and 2 closed out — a net gain of 3 holders — while 8 added to existing stakes and 11 trimmed.
The largest buyer was Fort Baker Capital Management, opening a new position worth an estimated $10.6M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $7.12M sold.
- 51 institutional investors held Oaktree Acquisition Corp III Life Sciences (OACC) as of Q1 2026, up from 49 in Q4 2025.
- Funds reported $179M of Oaktree Acquisition Corp III Life Sciences stock for Q1 2026, up 0.14% quarter-over-quarter.
- 5 funds opened new Oaktree Acquisition Corp III Life Sciences positions in Q1 2026 and 2 closed out, a net change of +3 holders.
- The largest Oaktree Acquisition Corp III Life Sciences buyer in Q1 2026 was Fort Baker Capital Management, an estimated $10.6M added.
- The largest Oaktree Acquisition Corp III Life Sciences seller in Q1 2026 was Driehaus Capital Management, an estimated $7.12M sold.
Based on aggregated 13F filings for Q1 2026.